drugset / Trial / NCT05925140
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
Phase 1
Unknown
1000 enrolled
Lebanese University
Hospital Saydet Zgharta University Medical Center · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study aims first to assess the efficacy, safety, and effectiveness of the LUSZ COVID-19 therapy consisting of a comparative study of three different treatment approaches: antiviral, antiretroviral, and immunosuppressive IL-6 receptor antagonist, and second to identify high-risk factors and biomarkers associated with fatal outcomes in hospitalized COVID-19 patients. The study seeks to validate a novel predictive scoring model for disease progression and evaluate the impact of these treatments on mortality, admission to the intensive care unit (ICU), and time to recovery.
Timeline
- Start
- 2020-03-28
- Primary completion
- 2024-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | 400 mg | Oral |
| Subject | Remdesivir | Small molecule | 100 mg | Intravenous |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |